Lipid peroxidation plays a critical role in cardiovascular diseases. Aldehydes are the major end products of lipid peroxidation and can be metabolized into less reactive chemical species by aldehyde dehydrogenase 2 (ALDH2). However, ALDH2 dehydrogenase activity can be affected by many factors including reactive oxygen species. To elucidate how reactive oxygen species inhibit ALDH2 dehydrogenase activity, we stimulated human aortic endothelial cells (HAECs) with oxidized low-density lipoproteins (ox-LDL) and performed a myocardial ischemia-reperfusion model. Ox-LDL treatment and ischemia-reperfusion injury inhibited ALDH2 dehydrogenase activity. Poly(ADP-ribose) polymerase (PARP) was activated by ox-LDL stimulation and ischemia-reperfusion injury and PARP inhibition partly restored ALDH2 dehydrogenase activity in ox-LDL treated HAECs and ischemia-reperfusion rat hearts. SIRT3 was upregulated by ox-LDL stimulation and ischemia-reperfusion injury and downregulated by PARP inhibition. Using siRNA to knock down SIRT3, we demonstrated that SIRT3 mediated deacetylation decreased ALDH2 dehydrogenase activity and PARP inhibition partly restored ALDH2 dehydrogenase activity through preventing SIRT3 expression and subsequently preserving ALDH2 acetylation.
Introduction
Lipid peroxidation plays a critical role in atherosclerosis [1] , myocardial hypertrophy [2] , heart failure [3] and other cardiovascular diseases [4] . Aldehydes are the major end products of lipid peroxidation and react with nucleic acids and proteins to generate various adducts that result in DNA damage/deletion/mutation and the inactivation of proteins [4] [5] [6] . Consequently, these aldehydes negatively affect normal functions of DNA and proteins, even directly promote cell or tissue damage [6] . Aldehydes can be metabolized into less reactive chemical species by glutathione S-transferases, aldo-keto reductases, aldehyde dehydrogenases, cytochromes P450 and phospholipase [4, 6] .
Aldehyde dehydrogenases (ALDHs) are a superfamily that consists of 19 distinct ALDH genes in the human genome [7] . ALDHs can convert toxic aldehydes to less toxic carboxylates. Among them, ALDH2 displays the highest affinity for acetaldehyde [4] . Moreover, ALDH2 can detoxify other aromatic and aliphatic aldehydes, including 4-hydroxy-2-nonenal (4HNE), which is a highly cytotoxic aldehyde. ALDH2 is a NAD + -dependent enzyme that primarily localizes to the mitochondria [5] . ALDH2 plays a critical role in many cardiovascular diseases, including coronary artery disease [8] , ischemia-reperfusion injury [9, 10] , diabetic cardiomyopathy [11, 12] , cardiac dysfunction [13] and myocardial hypertrophy [14] . However, the dehydrogenase activity of ALDH2 can be inhibited by many factors. ALDH2 dehydrogenase activity is regulated by several signal molecules, including protein kinase Cε (PKCε) [9] , c-Jun N-terminal kinase (JNK) [15] and SIRT3 [16, 17] . Moreover, ALDH2 dehydrogenase activity is redox sensitive [18] . Reactive oxygen species (ROS) and reactive nitrogen species (RNS) can also inhibit ALDH2 dehydrogenase activity. However, the mechanism how ROS decrease ALDH2 activity remains elusive.
Poly(ADP-ribose) polymerase (PARP) is an enzyme family that catalyzes the cleavage of nicotinamide adenine dinucleotide (NAD + ) into nicotinamide and ADP-ribose to form long branches of ADP-ribose polymers on glutamic acid residues of a number of target proteins [19] . DNA strand breaks induced by ROS lead to the activation of PARP. PARP overactivation results in the rapid depletion of intracellular NAD + [20] . ROS inhibit ALDH2 activation but activate PARP. PARP activation depletes intracellular NAD + and ALDH2 is a mitochondrial NAD + -dependent enzyme. Therefore, we speculate that PARP activation may participate in the ROS-induced inhibition of ALDH2 dehydrogenase activity.
In the present study, we examined the effect of oxidized lowdensity lipoproteins (ox-LDL) on ALDH2 activity in human aortic endothelial cells (HAECs) and the effect of ischemia-reperfusion injury on ALDH2 activity in rat hearts. We found that ox-LDL and ischemia reperfusion injury obviously reduced ALDH2 activity and PARP inhibition partly restored ALDH2 activity in HAECs and rat hearts. Furthermore, SIRT3 might be the downstream molecule through which PARP regulates ALDH2 dehydrogenase activity.
Materials and methods

Materials
Ox-LDL was purchased from Yuanyuan Biotech (Guangzhou, China). 3, 4-Dihydro-5[4-(1-piperindinyl)butoxy]-1(2H)-isoquinoline (DPQ), apocynin, rotenone, Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), allopurinol and N-acetyl-L-cysteine (NAC) were purchased from Sigma-Aldrich (Louis, MO, USA). The following primary antibodies were used: anti-ALDH2 and anti-β-actin were purchased from Santa Cruz (CA, USA), anti-poly(ADP-ribose) (PAR) was from Alexis (San Diego, CA, USA), anti-SIRT-3 and anti-acetyl lysine antibody were from Cell Signaling Technology (Danvers, MA, USA), and anti-gp91phox, anti-GAPDH and anti-COX IV antibody were from abcam (San Francisco, CA, USA). All secondary antibodies were purchased from Cell Signaling Technology.
Cell culture
HAECs purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) were cultured in endothelial cell medium (Sciencell, Carlsbad, CA, USA) containing 5% fetal bovine serum in a humidified atmosphere with 5% CO 2 and 95% air at 37°C. Passages 3-5 of cells were used for experiments. HAECs were stimulated with ox-LDL at different concentrations for different times. If necessary, apocynin (500 μM), rotenone (5 μM), L-NAME (100 μM), allopurinol (50 μM), NAC (10 mM) or DPQ (10 μM) was used to treat HAECs 1 hour before ox-LDL (100 μg/ml) stimulation.
Acute myocardial ischemia reperfusion model
A total of 40 male Wistar rats weighing approximately 250 g were divided into 4 groups: control group; DPQ group; ischemia-reperfusion (IR) group and IR+ DPQ group. These rats were anesthetized with intraperitoneal 3% pentobarbital (45 mg/kg) and ventilated via a tracheostomy on a Harvard rodent respirator. Half of the rats were intraperitoneally injected with 5 mg/kg DPQ 30 minutes before surgery. The heart was exposed via a left thoracotomy. In the IR group and IR +DPQ group, the proximal left anterior descending artery (LAD) was ligated using a 7-0 prolene suture with a slipknot for 30 minutes and the knot was then released allowing the heart to reperfuse for 120 minutes. To differentiate between ischemic and nonischemic tissue, 1 ml of Evans blue dye (2% in PBS) was injected into the left ventricular cavity to measure the myocardial ischemic area at risk. The heart was removed and sectioned into 3-mm slices. 2, 3, 5-Triphenyltetrazolium chloride (TTC, Sigma-Aldrich) was used to assess myocardial tissue viability and determine the myocardial infarct size. The tissue slices were incubated in 1% TTC PBS solution at 37°C for 20 minutes. Images of each slice were captured and the myocardial area at risk and infract area were quantified. All the animal experiments were approved by the Animal Care and Use Committee of Shandong University, in accordance with AAALAC guidelines.
ALDH2 activity assay
Mitochondria were isolated from HAECs with the Cell Mitochondria Isolation Kit (Beyotime, Haimen, China) and from myocardial tissue with the Tissue Mitochondrial Isolation Kit (Beyotime). Mitochondrial purity was assessed by western blot analysis (Supplemental data). Then, the protein concentration was determined with a BCA Protein Assay Kit (Beyotime). ALDH2 dehydrogenase activity was determined by the reaction rate of the conversion of NAD + to NADH at 340 nm in a Thermo Fisher Varioskan Flash spectral scanning multimode reader (Thermo Fisher) with the Cell Acetaldehyde Dehydrogenase Assay Kit (Genemed, Shanghai, China). The dehydrogenase activity of ALDH2 was expressed as nmol/mg protein/minute.
Western blotting
HAECs and myocardial tissue were lysed with RIPA Lysis Buffer (Beyotime) containing 1 mM PMSF. Protein samples were separated on 15% polyacrylamide gels and transferred onto polyvinylidene fluoride membranes. After blocking in 5% non-fat milk for 2 hours, the membranes were incubated with primary antibodies against ALDH2, β-actin and SIRT3 overnight at 4°C. On the second day, after being washed 3 times with TBST for 5 minutes, the membranes were incubated with corresponding horseradish peroxidase-labeled secondary antibodies and visualized with enhanced chemiluminescence substrate (Millipore, Billerica, MA).
ROS assay
HAECs in 6-well plates were incubated with 100 μg/ml ox-LDL for 2 hours. After being washed twice with PBS, ROS were determined with the Reactive Oxygen Species Kit (Beyotime). Briefly, cells were incubated with DCFH-DA at 37°C for 20 minutes. Within cells, DCFH reacted with ROS to produce fluorescent DCF. The ROS level was examined in a Thermo Fisher Varioskan Flash spectral scanning multimode reader. For the fluorescence detection of ROS, the wavelength was 488 nm for excitation and 580 nm for emission.
Immunofluorescence and immunohistochemistry
HAECs cultured on glass coverslips were fixed in 4% paraformaldehyde for 20 minutes, and then permeabilized with 0.01% Triton X-100 for 5 minutes. After being blocked in 10% rabbit serum for 1 hour, the cells were incubated with a primary antibody against PAR overnight at 4°C. On the second day, FITC-conjugated secondary antibody was added to bind the primary antibody. Finally, images were captured with a laser scanning confocal microscope. Rat hearts embedded in paraffin were cross-sectioned into 5-μm slices. After rehydration in PBS, sections were incubated with a primary antibody against PAR overnight at 4°C and the appropriate biotinylated secondary antibody. Subsequently, a 3,3′-diaminobenzidine (DAB) Kit was used to visualize the primary antibody. Images were analyzed using Image Pro-Plus software.
NAD + assay
A cellular NAD + assay was performed with the NAD + /NADH Assay Kit (Abcam, San Francisco, CA). The cells were washed with cold PBS and extracted the cells with NADH/NAD + Extraction Buffer by freeze/thaw two cycles. After adding NADH developer for 2 hours at room temperature, total NADt and NADH were detected at 450 nm A, HAECs were treated with apocynin (500 μM), rotenone (5 μM), L-NAME (100 μM), allopurinol (50 μM) or NAC (10 mM) for 1 hour and then stimulated with or without 100 μg/ml ox-LDL for 2 hours. After incubation with DCFH-DA, ROS production was determined and the relative mean DCF fluorescence is presented compared with the control. B and C, HAECs were stimulated with 100 μg/ml ox-LDL for 2 hours with or without pretreatment with 10 mM NAC. PAR expression was determined by immunofluorescence, and the relative expression was quantitatively analyzed, Bar = 50 μm. n =5. 
Immunoprecipitation
Cells and myocardial tissue were lysed in non-denaturing cell lysis buffer containing protease inhibitors. Whole cell lysates were incubated with an antibody against ALDH2 for 1 hour followed by protein (A/G)-agarose beads (Santa Cruz Biotechnology) overnight. The immunocomplexes were washed three times and resuspended in RIPA buffer. Supernatants were subjected to SDS-PAGE and probed for acetyl lysine and ALDH2.
Knockdown of SIRT3 by siRNA interference
The SIRT3 siRNA used in this study was purchased from Gene Pharma (Shanghai, China). The cells were transfected with negative control siRNA or SIRT3 siRNA using Lipofectamine 2000 Transfection Reagent (Invitrogen).
Statistical analysis
Data are presented as means ± standard error (S.E.M). Differences between two groups were evaluated using a two-tailed Student's t-test. One way ANOVA was used to analyze data from more than two groups. A value of P b 0.05 was considered statistically significant.
Results
Ox-LDL stimulation decreased ALDH2 dehydrogenase activity in HAECs
The effects of ox-LDL on ALDH2 dehydrogenase activity were determined in cultured HAECs. Fig. 1A shows that a time-dependent decrease in ALDH2 enzyme activity was induced by 100 μg/ml ox-LDL. The maximum effect was observed at 2 hours (46.8% decrease vs. control, P b 0.01; Fig. 1A) . The dose response of the ox-LDL effect was also measured in HAECs at 2 hours. ALDH2 dehydrogenase activity decreased gradually in a dose-dependent manner (Fig. 1C) . 100 μg/ml ox-LDL effectively decreased ALDH2 dehydrogenase activity at 2 hours, therefore, this concentration was used for subsequent experiments. No changes were found in ALDH2 protein expression (Fig. 1B and D) in HAECs stimulated with ox-LDL at different time points or different concentrations.
Ox-LDL treatment induced PARP activation by increasing the intracellular ROS level in HAECs
To determine how ox-LDL decreases ALDH2 activity in HAECs, we first tested the effect of ox-LDL on intracellular ROS production in HAECs. As expected, 100 μg/ml ox-LDL increased the ROS production in HAECs at 2 hours ( Fig. 2A) . To determine the sources of ROS in ox-LDL treated HAVECs, apocynin (500 μM, an inhibitor of NAPDH oxidase), rotenone (5 μM, an inhibitor of mitochondrial electron transport chain complex I), L-NAME (100 μM, an inhibitor of nitric oxide synthase), and allopurinol (50 μM, an inhibitor of xanthine oxidase) were used. As shown in Fig. 2A , apocynin significantly reduced the ROS production induced by ox-LDL, indicating that NAPDH oxidase is the major source of ROS in ox-LDL treated HAECs. The inhibitors rotenone and L-NAME also inhibited the ROS production induced by ox-LDL stimulation. Therefore, mitochondria and uncoupled endothelial nitric oxide synthase also contribute to increased ROS levels in ox-LDL treated HAECs. Excessive production of ROS can cause oxidative damage to DNA. PARP, a DNA damage sensor and signaling molecule can be activated by recognizing single or double-stranded DNA breaks [19] . Ox-LDL stimulation markedly activated PARP in HAECs (Fig. 2B and C) . Using NAC (10 mM), we found that excessive ROS production was effectively blocked by this antioxidant in ox-LDL treated HAECs (Fig. 2A) . Moreover, NAC significantly prevented PARP activation induced by ox-LDL stimulation (Fig. 2B and C) .
PARP inhibition partly prevented the ox-LDL induced inhibition of ALDH2 dehydrogenase activity in HAECs
To determine whether there was any relationship between ALDH2 dehydrogenase activity and PARP activation, the PARP inhibitor DPQ was used before ox-LDL stimulation. Pretreatment with DPQ effectively blocked ox-LDL induced PARP activation (Fig. 3A and B) , and interestingly, ALDH2 activity was partly restored by PARP inhibition in ox-LDL treated HAECs (Fig. 3C) . However, PARP inhibition did not change the protein expression of ALDH2 (Fig. 3D) . (Fig. 4B ). This finding indicated that PARP did not affect ALDH2 dehydrogenase activity by regulating the mitochondrial NAD + level.
PARP inhibition preserved ALDH2 acetylation by decreasing SIRT3 expression
Silent information regulator 2 (SIR2) is a family of proteins with NAD + -dependent deacetylase activity [21] . Seven isoforms of the mammalian SIR2 homolog, SIRT1-7, are expressed in mammals [22] . Recent studies indicated that SIRT3 regulates ALDH2 activity [16, 17] . SIRT3 is located in mitochondria and plays a role in the deacetylation of mitochondrial proteins [23] . Therefore, we evaluated the SIRT3 protein expression in ox-LDL treated HAECs. Accompanied by PARP activation, ox-LDL increased SIRT3 protein expression and PARP inhibition with DPQ inhibited the ox-LDL induced increase in SIRT3 protein level (Fig. 5A) . Inversely related to the protein level of SIRT3, ALDH2 acetylation, as indicated by acetyl lysine was decreased by ox-LDL and this effect was prevented by PARP inhibition (Fig. 5B ).
Selective knockdown of SIRT3 with siRNA preserved ALDH2 activity in ox-LDL treated HAECs
To confirm the role of SIRT3 in ALDH2 dehydrogenase activity, SIRT3 was knocked down with siRNA. Compared with nontransfected cells and nonsense siRNA-transfected cells, SIRT3 siRNA significantly inhibited SIRT3 protein expression (Fig. 6A) , and effectively increased ALDH2 acetylation in ox-LDL treated HAECs compared with ox-LDL treated HAECs and ox-LDL treated nonsense siRNA-transfected HAECs (Fig. 6B ). In accordance with previous studies [16, 17] , the activity of ALDH2 was preserved by SIRT3 inhibition in ox-LDL treated HAECs (Fig. 6C) . The protein level of ALDH2 was still not altered by the selective knockdown of SIRT3 (Fig. 6D) .
ALDH2 activity was preserved by PARP inhibition in ischemiareperfusion injured heart
To further confirm the role of PARP inhibition in ALDH2 dehydrogenase activity in vivo, we used a rat cardiac ischemia-reperfusion injury model. ROS play an important role in producing lethal cell injury during cardiac ischemia-reperfusion [24] , and PARP is activated in cardiac tissue following ischemia-reperfusion [25] . Using DPQ, PARP inhibition significantly reduced the myocardial infarct size compared with IR heart in our study (Fig. 7A) . Ischemia-reperfusion induced a marked increase in PAR expression compared with the control group and PARP inhibition effectively prevented PAR production in IR hearts (Fig. 7B) . Inversely related to PARP activation, ALDH2 dehydrogenase activity was inhibited in ischemic myocardial areas (Fig. 7C) . PARP inhibition was also found to be able to preserve ALDH2 activity in ischemia-reperfusion hearts (Fig. 7C ) without any change in the protein level of ALDH2 (Fig. 7D) . Moreover, ischemiareperfusion increased SIRT3 expression which was prevented by PARP inhibition in rat hearts (Fig. 7D) . In contrast to SIRT3 expression, ALDH2 acetylation was decreased by ischemia-reperfusion injury and preserved by PARP inhibition (Fig. 7E ).
Discussion
In the present study, we demonstrated that ox-LDL treatment and ischemia-reperfusion injury markedly decreased ALDH2 dehydrogenase activity and PARP inhibition partly restored ALDH2 activity in HAECs and rat hearts. Using SIRT3 siRNA, SIRT3 was found to contribute to the inhibitory effect of PARP activation on ALDH2 dehydrogenase activity by regulating ALDH2 acetylation.
ALDH2 has two types of enzyme activity: dehydrogenase activity, through which ALDH2 plays a critical role in aldehyde and ethanol metabolism [14, [26] [27] [28] , and esterase activity, which is related to the bioactivation of nitroglycerin [29] and nitrate tolerance [30] . Given the central role of lipid peroxidation in atherosclerosis and other heart diseases, the effects of aldehydes are likely to be particularly important in cardiovascular diseases [4] . Therefore, identifying the pathway regulating ALDH2 dehydrogenase activity benefits the treatment of cardiovascular diseases. Previous studies have shown that ALDH2 activity is inhibited by ROS [18, 31] . In the present study, we found that ox-LDL and ischemia-reperfusion injury decreased ALDH2 dehydrogenase activity.
The protein expression of ALDH2 may be downregulated by ROS in nitrate tolerance or diabetic rats [11, 32] . However, ALDH2 protein levels are unchanged or changed by a small amount after exposure to alcohol or hepatic ischemia-reperfusion injury [6, 16] . In the present study, we found that the protein level of ALDH2 was unchanged by ox-LDL treatment in HAECs and ischemia-reperfusion injury in rat hearts. Therefore, the inhibitory effect of ox-LDL treatment and ischemia-reperfusion injury on ALDH2 dehydrogenase activity was not mediated by the downregulation of ALDH2 protein but possibly by post-translational modifications.
PARP is a DNA repair enzyme that is sensitive to and activated by both single-and double-stranded DNA breaks [19] . Ox-LDL and ischemia-reperfusion injury increased ROS, which could damage DNA and consequently activate PARP [25] . As PARP overactivation consumes cellular NAD + , we tested whether PARP activation plays a role in inhibiting ALDH2 dehydrogenase activity. We found that PARP inhibition with DPQ partly restored ALDH2 dehydrogenase activity in ox-LDL treated HAECs. Although cellular NAD + was decreased, the level of mitochondrial NAD + was not changed by PARP activation [23, 33] . In the present study, we also found that the mitochondrial NAD + level was not changed by ox-LDL stimulation or PARP inhibition.
As ALDH2 is a mitochondrial NAD + -dependent enzyme, the effect of PARP on ALDH2 dehydrogenase activity should not be mediated through mitochondrial NAD + . Moreover, we found that the ALDH2 protein level was not altered by PARP inhibition. These findings further indicated that PARP inhibition restored ROS induced inhibition of ALDH2 dehydrogenase activity not through protein expression but by protein modification.
ALDH2 protein can be modified by various forms of posttranslational modifications, including oxidation, S-nitrosylation, phosphorylation, nitration, acetylation, glycosylation, and adduct formation [6] . Recently, deacetylation by SIRT3 has emerged as an important post-translational modification regulating the function of many mitochondrial proteins [34, 35] . The lysine of ALDH2 can also be acetylated [36] . The acetylation level of ALDH2 can be modified by SIRT3 and a reduction in ALDH2 deacetylation could maintain ALDH2 dehydrogenase activity [16, 17] . In primary cultured mouse cortical neurons, PARP activation mediated NAD + depletion and subsequently increased in mitochondrial SIRT3 [33] . Similarly, we found that PARP activation by ox-LDL significantly decreased the cellular NAD + level and increased SIRT3 expression, which led to a decrease in ALDH2 acetylation in HAECs. Furthermore, PARP inhibition prevented SIRT3 upregulation and preserved ALDH2 acetylation. To confirm the role of deacetylation by SIRT3 on ALDH2 dehydrogenase activity, SIRT3 was selectively knocked down with siRNA in ox-LDL treated HAECs and we found that SIRT3 could affect ALDH2 dehydrogenase activity by regulating the lysine acetylation of ALDH2. The in vivo study also indicated that PARP overactivation inhibited ALDH2 dehydrogenase activity and increased SIRT3 expression in ischemia-reperfusion rat hearts. Consistent with the results from in vitro study, PARP inhibition restored ALDH2 activity, prevented the increase in SIRT3 expression and subsequently maintained the acetylation level of ALDH2 in ischemiareperfusion rat hearts. Therefore, PARP might affect ALDH2 dehydrogenase activity through the SIRT3 pathway, which regulates ALDH2 acetylation.
In conclusion, our study demonstrated that ox-LDL and ischemiareperfusion injury effectively decreased ALDH2 dehydrogenase activity and PARP inhibition preserved the dehydrogenase activity of ALDH2 by preventing an increase in SIRT3 expression and maintaining the acetylation level of ALDH2.
Supplementary data to this article can be found online at http:// dx.doi.org/10.1016/j.bbamcr.2012.11.007.
